[18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management
Abstract A 47‐year‐old woman underwent [18F]‐FDG and [18F]‐NOTA‐FAPI‐04 PET/CT to assess the staging of suspected axillary lymph node enlargement following breast‐conserving surgery. The imaging with these two PET agents revealed starkly contrasting results. Significant [18F]‐FDG uptake in the right...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Precision Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pro6.1245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846107400256356352 |
|---|---|
| author | Jingjie Qin Jingjing Zhao Jinming Yu Yuchun Wei |
| author_facet | Jingjie Qin Jingjing Zhao Jinming Yu Yuchun Wei |
| author_sort | Jingjie Qin |
| collection | DOAJ |
| description | Abstract A 47‐year‐old woman underwent [18F]‐FDG and [18F]‐NOTA‐FAPI‐04 PET/CT to assess the staging of suspected axillary lymph node enlargement following breast‐conserving surgery. The imaging with these two PET agents revealed starkly contrasting results. Significant [18F]‐FDG uptake in the right axillary fossa, intrathoracic muscles, and clavicle lymph nodes led nuclear medicine physicians to suspect metastasis. However, no uptake of [18F]‐NOTA‐FAPI‐04 was observed. Subsequently, the patient underwent an ultrasound‐guided biopsy of the enlarged axillary lymph nodes, which pathologically confirmed the diagnosis as inflammation. After a multidisciplinary discussion, the patient received radiotherapy for the right breast and 2.15Gy/F×28F for the tumor bed. She was discharged following the completion of her radiotherapy. Accurate diagnosis and staging are pivotal in selecting the optimal clinical treatment for breast cancer patients. Notably, [18F]‐NOTA‐FAPI‐04 PET/CT downgraded this patient's staging, significantly influencing the treatment strategy. |
| format | Article |
| id | doaj-art-194b8b724f804196b0ba0e4660dda837 |
| institution | Kabale University |
| issn | 2398-7324 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Precision Radiation Oncology |
| spelling | doaj-art-194b8b724f804196b0ba0e4660dda8372024-12-26T13:26:48ZengWileyPrecision Radiation Oncology2398-73242024-12-018422723110.1002/pro6.1245[18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment managementJingjie Qin0Jingjing Zhao1Jinming Yu2Yuchun Wei3Department of Radiology Shandong Cancer Hospital and Institute Shandong First Medical University Shandong Academy of Medical Sciences Jinan Shandong Province ChinaDepartment of Radiology Shandong Cancer Hospital and Institute Shandong First Medical University Shandong Academy of Medical Sciences Jinan Shandong Province ChinaDepartment of Radiology Shandong Cancer Hospital and Institute Shandong First Medical University Shandong Academy of Medical Sciences Jinan Shandong Province ChinaDepartment of Radiology Shandong Cancer Hospital and Institute Shandong First Medical University Shandong Academy of Medical Sciences Jinan Shandong Province ChinaAbstract A 47‐year‐old woman underwent [18F]‐FDG and [18F]‐NOTA‐FAPI‐04 PET/CT to assess the staging of suspected axillary lymph node enlargement following breast‐conserving surgery. The imaging with these two PET agents revealed starkly contrasting results. Significant [18F]‐FDG uptake in the right axillary fossa, intrathoracic muscles, and clavicle lymph nodes led nuclear medicine physicians to suspect metastasis. However, no uptake of [18F]‐NOTA‐FAPI‐04 was observed. Subsequently, the patient underwent an ultrasound‐guided biopsy of the enlarged axillary lymph nodes, which pathologically confirmed the diagnosis as inflammation. After a multidisciplinary discussion, the patient received radiotherapy for the right breast and 2.15Gy/F×28F for the tumor bed. She was discharged following the completion of her radiotherapy. Accurate diagnosis and staging are pivotal in selecting the optimal clinical treatment for breast cancer patients. Notably, [18F]‐NOTA‐FAPI‐04 PET/CT downgraded this patient's staging, significantly influencing the treatment strategy.https://doi.org/10.1002/pro6.1245breast cancerfibroblast activation proteinPET |
| spellingShingle | Jingjie Qin Jingjing Zhao Jinming Yu Yuchun Wei [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management Precision Radiation Oncology breast cancer fibroblast activation protein PET |
| title | [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management |
| title_full | [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management |
| title_fullStr | [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management |
| title_full_unstemmed | [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management |
| title_short | [18F]‐NOTA‐FAPI‐04 PET/CT downgraded the staging of a breast cancer patient and changed their treatment management |
| title_sort | 18f nota fapi 04 pet ct downgraded the staging of a breast cancer patient and changed their treatment management |
| topic | breast cancer fibroblast activation protein PET |
| url | https://doi.org/10.1002/pro6.1245 |
| work_keys_str_mv | AT jingjieqin 18fnotafapi04petctdowngradedthestagingofabreastcancerpatientandchangedtheirtreatmentmanagement AT jingjingzhao 18fnotafapi04petctdowngradedthestagingofabreastcancerpatientandchangedtheirtreatmentmanagement AT jinmingyu 18fnotafapi04petctdowngradedthestagingofabreastcancerpatientandchangedtheirtreatmentmanagement AT yuchunwei 18fnotafapi04petctdowngradedthestagingofabreastcancerpatientandchangedtheirtreatmentmanagement |